Junshi Biosciences, based in Shanghai, China, announced that an Independent Monitoring Committee (IDMC) decided the company’s Phase III JUPITER-02 trial had met the pre-specified primary endpoint at the interim analysis.
Johnson & Johnson Dives Into 2018 With 15 New Deals
Adeno-Associated Virus (AAV), Alzheimer's Disease, Artificial Intelligence, Collaborations, COPD, Deals, Diabetes, Diagnostics, Digital Health, Elderly, G-Protein-Coupled Receptors, Gene Therapy, Lung Cancer, Microbiome, Myopia, Neurodegenerative Diseases, Neuroscience, Oncology, Ophthalmology, Skin Conditions, Throat CancerJohnson & Johnson Innovation kick started 2018 by striking collaborative agreements with 15 different organizations and companies to address areas of high unmet medical need in neuroscience, oncology and other areas.